Navigation Links
Lexicon to Present at Stifel Nicolaus Healthcare Conference
Date:9/9/2010

THE WOODLANDS, Texas, Sept. 9 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. Arthur T. Sands, president and chief executive officer, will present at the Stifel Nicolaus Healthcare Conference in Boston on Thursday, September 16, 2010 at 9:10 a.m. Eastern Time.

A live webcast of the presentation will be accessible through Lexicon's corporate website at www.lexpharma.com. An archived edition of the presentation will also be available for 30 days after the event.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon to Present at Morgan Stanley Global Healthcare Conference
2. Lexicon to Present at Two Major Healthcare Investor Conferences
3. Lexicon Announces Pricing of Common Stock in Public Offering
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
5. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
6. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
8. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
9. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
10. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
11. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased to announce Doug Obermann ... began his career at PBI-Gordon in February 1988, after finishing his masters in agronomy ... ranging from customer service to national product manager, to helping develop, name and launch ...
(Date:5/3/2016)... ... 03, 2016 , ... In a list published by the Boston Business Journal, ... private companies; a small percentage of the state's 615,000+ small businesses. The list examined ... in revenue from 2012 to 2015. , As this award comes on ...
(Date:5/3/2016)... ... May 03, 2016 , ... Wearable Tech + Digital ... will take place on June 7-8, 2016, at the New York Academy of Sciences.  ... technology -- including AR/VR, machine learning, apps, robotics and AI -- throughout a major ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... clinics and IVF laboratories. A contingency of reproductive endocrinologists, including Dr. George ... women experiencing infertility and to help them build families. , Ovation Fertility is ...
Breaking Biology Technology:
(Date:3/14/2016)... March 14, 2016 http://www.apimages.com ... --> - Renvoi : image disponible via ... --> --> DERMALOG, le ... de nouveaux lecteurs d,empreintes digitales pour l,enregistrement des ... sera utilisé pour produire des cartes d,identité aux ...
(Date:3/10/2016)... BELL, Pa. , March 10, 2016   Unisys ... U.S. Customs and Border Protection (CBP) is testing its ... San Diego to help identify certain ... States . The test, designed to help determine the ... pedestrian environment, began in February and will run until May ...
(Date:3/8/2016)...   Valencell , the leading innovator in ... secured $11M in Series D financing. The investment ... fund being launched by UAE-based financial services company ... TDF Ventures and WSJ Joshua Fund. Valencell plans ... growth and accelerate its pioneering innovation in accurate ...
Breaking Biology News(10 mins):